Medical disclaimer

Five-Fraction Proton Therapy for Skull Base Chordoma and Chondrosarcoma: Early Results

In a small early series of 11 adults, five-fraction proton therapy for skull base chordoma and chondrosarcoma was reported with 100% local control at a median follow-up of 12 months, and two patients had late grade 3 temporal lobe necrosis. The patients were treated at Centro de Protonterapia Quironsalud in Pozuelo de Alarcón, Madrid, which is the Proton Therapy Centre Quironsalud listed on Bookimed under its English name.

8 min read

Prepared by Bookimed editorial team

Medical content and care coordination

Proton Therapy Centre Quironsalud
← All research summaries
Published research, not an individual patient story.

The source identifies treatment at the named clinic. Study results describe this cohort, not a predicted individual outcome.

Key takeaways

  • The series included 11 adults: 6 with chordoma and 5 with chondrosarcoma of the skull base.
  • Local control was 100% at a median follow-up of 12 months (range 9-15 months).
  • Acute side effects included grade I-II headache (64%), grade I asthenia and alopecia (45%), grade I nausea (27%) and grade I dysphagia (18%).
  • Two patients had late grade 3 temporal lobe necrosis.
  • The authors call the results encouraging but preliminary and say larger trials with longer follow-up are needed.

The question this study addresses

This paper describes the design of a phase II trial of proton therapy given in five fractions for skull base chordomas and chondrosarcomas, and reports early results from the first prospective series. The patients were treated at Centro de Protonterapia Quironsalud in Madrid, the same centre as the Proton Therapy Centre Quironsalud on Bookimed. The study looked at local control and clinical tolerance. Bookimed did not run the study.

The situation
Adults with a chordoma or chondrosarcoma at the base of the skull. Entry criteria were age of at least 18 years, Karnofsky Performance Status of at least 70% (a score of daily functioning), a clinical target volume of up to 50 cc, and compliance with dose limits for critical organs.
The treatment
Proton therapy with pencil beam scanning (a narrow proton beam steered over the tumor), using four to six beams. The planned dose was 37.5 GyRBE in five fractions for chordomas and 35 GyRBE in five fractions for chondrosarcomas.

What this evidence cannot establish

  • Only 11 patients were included, and results are given for the whole series, not separately for chordoma and chondrosarcoma.
  • Median follow-up was 12 months, which is short for these tumors, and the authors say longer follow-up is needed.
  • The study was run at one centre, the same centre that is the clinic on this page, so it is not an independent check of that clinic's results.

Patient groups in the published study

6 patients · Published study group

Skull base chordoma treated with 5-fraction proton therapy

Indication
Skull base chordoma
Treatment
Proton therapy, 37.5 GyRBE in five fractions, pencil beam scanning

6 adult patients with chordoma in the series of 11.

Adults with a chordoma at the base of the skull who met the trial entry criteria on age, performance status, tumor volume and dose limits to critical organs.

37.5 GyRBE in five fractions with pencil beam scanning, using four to six beams.

  • Local control (reported for the whole study, which includes this group)

    100%

    6 patients · Study group

    median 12 months (9-15 months)

Reported risks

  • These are study-wide items, not specific to chordoma: acute headache, asthenia, alopecia, nausea and dysphagia were reported, and two patients in the whole series had late grade 3 temporal lobe necrosis.

Limits of this evidence

  • Outcomes are not reported separately for chordomas; local control and toxicity are given for the whole series only.
  • The group is small and the follow-up is short.

For a clinic assessment

  • Recent MRI or CT reports and images of the skull base tumor
  • Pathology report confirming the diagnosis

5 patients · Published study group

Skull base chondrosarcoma treated with 5-fraction proton therapy

Indication
Skull base chondrosarcoma
Treatment
Proton therapy, 35 GyRBE in five fractions, pencil beam scanning

5 adult patients with chondrosarcoma in the series of 11.

Adults with a chondrosarcoma at the base of the skull who met the trial entry criteria on age, performance status, tumor volume and dose limits to critical organs.

35 GyRBE in five fractions with pencil beam scanning, using four to six beams.

  • Local control (reported for the whole study, which includes this group)

    100%

    5 patients · Study group

    median 12 months (9-15 months)

Reported risks

  • These are study-wide items, not specific to chondrosarcoma: acute headache, asthenia, alopecia, nausea and dysphagia were reported, and two patients in the whole series had late grade 3 temporal lobe necrosis.

Limits of this evidence

  • Outcomes are not reported separately for chondrosarcomas; local control and toxicity are given for the whole series only.
  • The group is small and the follow-up is short.

For a clinic assessment

  • Recent MRI or CT reports and images of the skull base tumor
  • Pathology report and any earlier treatment summaries

Results and limits of the study

Across all 11 patients, local control was 100% at a median follow-up of 12 months (range 9-15 months). Acute grade I-II headache occurred in 64%, grade I asthenia and alopecia in 45%, grade I nausea in 27% and grade I dysphagia in 18%. These are group results from a small series and are not a forecast for any individual patient.

  • Local control

    100%

    11 patients · Whole cohort

    median 12 months (9-15 months)

  • Acute grade I-II headache

    64%

    11 patients · Whole cohort

    not stated

  • Grade I asthenia and alopecia

    45%

    11 patients · Whole cohort

    not stated

  • Grade I nausea

    27%

    11 patients · Whole cohort

    not stated

  • Grade I dysphagia

    18%

    11 patients · Whole cohort

    not stated

  • Late grade 3 temporal lobe necrosis

    2 / 11

    11 patients · Whole cohort

    not stated

Risks reported by the source

  • Acute grade I-II headache (64%).
  • Grade I asthenia and alopecia (45%), grade I nausea (27%) and grade I dysphagia (18%).
  • Late grade 3 temporal lobe necrosis in two of 11 patients.

Limitations and unknowns

  • Results are not split between chordoma and chondrosarcoma.
  • It is not known how local control and late effects look beyond a median of 12 months.
  • The abstract does not compare five-fraction treatment with other schedules.
  • The abstract does not say how many patients had earlier treatment.

What to clarify in your treatment plan

Before booking, ask the clinic whether your tumor type, size and position near critical organs would fit the criteria used in this trial. Ask which dose schedule and follow-up imaging plan would be proposed, and how late effects are monitored. Ask which records the team needs to review your case.

Proton Therapy Centre Quironsalud: clinic profile

  • The study patients were treated at Centro de Protonterapia Quironsalud in Pozuelo de Alarcón, Madrid, which is the same centre as Proton Therapy Centre Quironsalud.
  • All authors list this centre, and no other treating hospital is named in the abstract.
  • The clinic profile is available on Bookimed.

Daniel Alejandro Mazal: doctor profile

  • Daniel Alejandro Mazal, matched to the Bookimed profile, is listed as the tenth author of the paper with the Centro de Protonterapia Quironsalud affiliation.
  • The abstract does not describe his specific role in the study.
Daniel Alejandro Mazal

Daniel Alejandro Mazal

Nuclear medicine physician

42 years of experience

Safety and recovery: general information

General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.

Possible side effects

  • Proton therapy may cause fatigue, and side effects may depend on the type or location of the tumor.

    Ask the team which side effects are most likely for a skull base tumor and how they are managed.

  • Hair loss and skin problems on the treated area, such as redness, irritation, dryness or tenderness, can happen.

    Ask how to care for the skin and scalp during treatment.

Recovery and aftercare

  • Fatigue can happen during treatment and may continue afterward.

    Ask the clinic how long to plan for rest and when to resume usual activities.

Suitability and cautions

  • Proton therapy can't be used for every cancer, so it may not suit every patient.

    Ask the clinic to confirm in writing whether your diagnosis and tumor position make you a candidate.

When to contact the clinic

  • Tiredness that is severe or does not ease after treatment, or skin changes on the treated area that worry you.

    Contact the treating team and describe the symptom and when it started.

Request a personal plan from the clinic

Ask Proton Therapy Centre Quironsalud about proton therapy for a skull base chordoma or chondrosarcoma

Send your diagnosis and imaging reports to the Bookimed coordinator, who passes them to the clinic and asks whether your case may fit this type of treatment. The clinic, not Bookimed, makes the medical decision.

Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.

Frequently asked questions

Who ran this study and where were the patients treated?

The study was run by authors at Centro de Protonterapia Quironsalud in Pozuelo de Alarcón, Madrid, and the patients were treated there. This is the same centre as Proton Therapy Centre Quironsalud on Bookimed, listed under its Spanish name. All authors list this centre, and no other treating hospital is named. Bookimed did not run or fund the study; this page summarizes the published abstract.

What did the study find about local control?

Local control was 100% across the 11 patients at a median follow-up of 12 months (range 9-15 months). This is a small early series, and the abstract does not give results separately for chordoma and chondrosarcoma. The authors call the results encouraging but preliminary, and these group results do not predict what will happen for an individual patient.

What side effects were reported?

Acute grade I-II headache occurred in 64% of patients, grade I asthenia and alopecia in 45%, grade I nausea in 27% and grade I dysphagia in 18%. Two patients had late grade 3 temporal lobe necrosis. These figures come from 11 patients, so they are rough and may differ for other groups. Ask the clinic what applies to your tumor.

Who was included in the trial?

The trial included adults aged 18 or older with a skull base chordoma or chondrosarcoma and a Karnofsky Performance Status of at least 70%. The clinical target volume had to be up to 50 cc, and dose limits to critical organs had to be met. Chordomas were planned for 37.5 GyRBE and chondrosarcomas for 35 GyRBE, each in five fractions. Whether you would qualify is for the clinic to decide.

Sources and scope

This page was prepared from the published abstract of the study and its extracted results, with general safety information taken from American Cancer Society text. Bookimed did not run the study and added no new data.

  1. 1. Sallabanda et al. – Five-Fraction Proton Therapy for the Treatment of Skull Base Chordomas and Chondrosarcomas: Early Results of a Prospective Series and Description of a Clinical Trial.

    Prospective single-centre series, early results of a phase II trial · 2023

    11 adults with skull base chordoma (6) or chondrosarcoma (5)

    Follow-up: Median 12 months (range 9-15 months)

    The abstract reports a small single-centre series with short follow-up and does not give results by tumor type.

  2. 2. American Cancer Society
  3. 3. Proton Therapy Centre Quironsalud on Bookimed
  4. 4. Daniel Alejandro Mazal on Bookimed

Scope and limitations

  • A research summary is not an individual medical recommendation.
  • Group results describe the study participants, not a forecast for any one patient.

Related procedures

About the editorial team

Bookimed editorial team

Prepared by

Bookimed editorial team

Medical content and care coordination

Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.

About this page

This page summarizes cited evidence and links to current Bookimed provider profiles. It does not replace an individual diagnosis or treatment plan. Published group results are not a guarantee of your outcome.

Clinic profiles and package availability come from the current Site catalog. Historical costs and research measurements keep their original context.

Report a correction